https://www.cytiva.com/FlexFactoryFlexFactory from Cytiva gives rapid access to cGMP manufacturing capacity for key biologics such as mAbs and vaccines from cell culture to bulk product formulation.
Tailored to fit a new or existing facility, the extensive application of single-use technology gives the flexibility to modify individual processes as production needs change or to develop a completely new production line for your facility within 9 to 12 months.
